# Wegovy: what it is, and the honest evidence

> What Wegovy actually is: the molecule (semaglutide), its FDA-approved weight-management and heart-risk uses, how it differs from Ozempic and Zepbound, and honest, evidence-graded answers on results, side effects, and the myths.

**Type:** Brand hub · **Molecule:** semaglutide · **Maker:** Novo Nordisk · **Source page:** https://thepeptideera.com/wegovy

## At a glance
Wegovy is a brand name for semaglutide, a GLP-1 receptor agonist made by Novo Nordisk and FDA-approved for chronic weight management (and, since 2024, for reducing cardiovascular risk in adults with obesity or overweight who also have heart disease). It is the same molecule as Ozempic; the difference is the approved use and the dose ceiling studied for each. The headline obesity weight-loss numbers come from Wegovy’s trial program.

## Facts
- **Molecule:** semaglutide
- **How it works:** a GLP-1 receptor agonist
- **Maker:** Novo Nordisk
- **Form:** a once-weekly injection
- **FDA-approved for:** chronic weight management, and reducing cardiovascular risk in adults with obesity or overweight plus established heart disease
- **Sibling brand:** Ozempic — the same molecule, approved for type 2 diabetes

## Evidence
- [Zepbound vs Wegovy: what the head-to-head evidence shows](https://thepeptideera.com/evidence/zepbound-vs-wegovy) — The head-to-head with the dual-agonist, Zepbound.
- [Are Ozempic and Wegovy the same drug?](https://thepeptideera.com/evidence/are-ozempic-and-wegovy-the-same-drug) — Wegovy vs Ozempic — same molecule, different approved use.
- [Semaglutide side effects: what the evidence actually shows](https://thepeptideera.com/evidence/semaglutide-side-effects) — What the evidence shows about semaglutide’s side effects.
- [Semaglutide vs tirzepatide: how they really compare](https://thepeptideera.com/evidence/semaglutide-vs-tirzepatide) — How semaglutide compares with tirzepatide on weight loss.
- [What happens when you stop GLP-1 medications?](https://thepeptideera.com/evidence/stopping-glp1) — What the evidence says happens when you stop.
- [Keeping weight off after stopping a GLP-1](https://thepeptideera.com/evidence/keeping-weight-off-after-glp1) — Holding the result — the maintenance question.

## Myths, graded
- "Ozempic works without any diet or exercise changes." — Misleading — the trials that proved it work paired the drug with diet and activity (https://thepeptideera.com/myths/ozempic-works-without-diet-exercise)
- "GLP-1s like Ozempic and Wegovy are the easy way out — taking them is just cheating instead of doing the real work of diet and willpower." — Misleading value judgment, not a medical fact (https://thepeptideera.com/myths/glp1-easy-way-out)
- "Ozempic ruins your metabolism — once you take it, your metabolism is permanently damaged and you'll gain all the weight back (and then some) the moment you stop." — Misleading overstatement (https://thepeptideera.com/myths/ruins-metabolism)
- "You can just stop taking it once you hit your goal weight." — Misleading overstatement (https://thepeptideera.com/myths/stop-at-goal)
- "You lose mostly muscle on GLP-1s, not fat." — Mostly false — you lose mostly fat, but some lean loss is real (https://thepeptideera.com/myths/mostly-muscle-loss)
- "You have to take it forever — it's a life sentence." — Mostly true on the biology, loaded in the framing — obesity is chronic, so stopping usually brings regain (https://thepeptideera.com/myths/glp1-forever-life-sentence)

## Sources (2)
1. WEGOVY (semaglutide) injection — FDA Prescribing Information (DailyMed) — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b [LABEL]
2. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems in Adults with Obesity or Overweight (Wegovy, 2024) — https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or [NEWS]

---
From The Peptide Era (https://thepeptideera.com) — evidence-graded, primary-sourced answers about GLP-1 medicines. Education, not medical advice. Not a buying guide. No doses, no sourcing.